Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Payables (2021 - 2025)

Senti Biosciences has reported Payables over the past 5 years, most recently at $5.4 million for Q4 2025.

  • For Q4 2025, Payables rose 268.23% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, up 268.23%, while the annual FY2025 figure was $5.4 million, 268.23% up from the prior year.
  • Payables for Q4 2025 was $5.4 million at Senti Biosciences, up from $5.1 million in the prior quarter.
  • Over five years, Payables peaked at $12.6 million in Q4 2022 and troughed at $28.0 in Q1 2021.
  • A 5-year average of $4.1 million and a median of $3.8 million in 2025 define the central range for Payables.
  • Biggest five-year swings in Payables: soared 14015194.12% in 2022 and later tumbled 76.34% in 2024.
  • Year by year, Payables stood at $5.3 million in 2021, then surged by 135.9% to $12.6 million in 2022, then tumbled by 52.87% to $5.9 million in 2023, then plummeted by 75.47% to $1.5 million in 2024, then skyrocketed by 268.23% to $5.4 million in 2025.
  • Business Quant data shows Payables for SNTI at $5.4 million in Q4 2025, $5.1 million in Q3 2025, and $3.6 million in Q2 2025.